Potential therapies for mitochondrial dysfunction

Mitochondrial Dysfunction in Neurodegenerative Disorders

Volumn , Issue , 2012, Pages 215-230

  Henchcliffe, Claire ^a   Beal, M Flint ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Alzheimer s disease; Coenzyme Q10; Creatine; Friedreich s ataxia; Huntington s disease; Mitochondrial therapy; Neuro protection; Neurodegeneration; Parkinson s disease

Indexed keywords

EID: 84872335260     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-701-3_13     Document Type: Chapter

References (100)

1. Thomas B, Beal MF. Mitochondrial therapies for Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S155-60.
2. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S189-94.
3. Burchell VS, Gandhi S, Deas E, et al. Targeting mitochondrial dysfunction in neurodegenerative disease: Part I. Expert Opin Ther Targets. 2010;14:369-85.
4. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9:829-40.
5. Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab. 2009;99:246-55.
6. Chinnery P, Majamaa K, Turnbull D, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2006; (1):CD004426.
7. Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007;35:235-42.
8. Yang L, Calingasan NY, Thomas B, et al. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. PLoS One. 2009;4:e5757.
9. Matthews RT, Yang L, Browne S, et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998;95: 8892-7.
10. Beal MF, Shults CW. Effects of Coenzyme Q10 in Huntington’s disease and early Parkinson’s disease. Biofactors. 2003;18:153-61.
11. Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009;5:597-610.
12. Shults CW. Therapeutic role of coenzyme Q(10) in Parkinson’s disease. Pharmacol Ther. 2005;107:120-30.
13. Geromel V, Rotig A, Munnich A, et al. Coenzyme Q10 depletion is comparatively less detrimental to human cultured skin fibroblasts than respiratory chain complex deficiencies. Free Radic Res. 2002;36:375-9.
14. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541-50.
15. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20-8.
16. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993;16:125-31.
17. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397-404.
18. Rustin P, Munnich A, Rotig A. Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced injury in vitro. Biofactors. 1999;9:247-51.
19. Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart. 2002;87:346-9.
20. Barbiroli B, Montagna P, Martinelli P, et al. Defective brain energy metabolism shown by in vivo 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J Cereb Blood Flow Metab. 1993;13:469-74.
21. Jin J, Meredith GE, Chen L, et al. Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson’s disease. Brain Res Mol Brain Res. 2005; 134:119-38.
22. Lodi R, Tonon C, Calabrese V, et al. Friedreich’s ataxia: from disease mechanisms to therapeutic interventions. Antioxid Redox Signal. 2006;8:438-43.
23. Cooper JM, Korlipara LV, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008; 15:1371-9.
24. Senin U, Parnetti L, Barbagallo-Sangiorgi G, et al. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr. 1992;15:249-60.
25. Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol. 1994;9:161-8.
26. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. J Neural Transm Suppl. 1998;54:301-10.
27. Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology. 1997;36:73-82.
28. Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology. 2003;61:1498-502.
29. Kaufmann P, Thompson JL, Levy G, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235-44.
30. Gualano B, Artioli GG, Poortmans JR, et al. Exploring the therapeutic role of creatine supplementation. Amino Acids. 2010;38:31-44.
31. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664-71.
32. Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo- controlled randomized pilot trial. Neurology. 2006;67:1262-4.
33. Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2007;21:107-15.
34. Tabrizi SJ, Blamire AM, Manners DN, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology. 2005;64:1655-6.
35. Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington’s disease: clinical and MRS findings in a 1-year pilot study. Neurology. 2003;61:141-2.
36. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology. 2006;66:250-2.
37. Atassi N, Ratai EM, Greenblatt DJ, et al. A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:508-13.
38. Chaturvedi RK, Adhihetty P, Shukla S, et al. Impaired PGC-1alpha function in muscle in Huntington’s disease. Hum Mol Genet. 2009;18:3048-65.
39. Andreassen OA, Ferrante RJ, Dedeoglu A, et al. Lipoic acid improves survival in transgenic mouse models of Huntington’s disease. Neuroreport. 2001;12:3371-3.
40. Andreassen OA, Dedeoglu A, Friedlich A, et al. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol. 2001;168:419-24.
41. Zembron-Lacny A, Szyszka K, Szygula Z. Effect of cysteine derivatives administration in healthy men exposed to intense resistance exercise by evaluation of pro-antioxidant ratio. J Physiol Sci. 2007;57:343-8.
42. Wang C, Sadovova N, Ali HK, et al. L-carnitine protects neurons from 1-methyl-4-phenylpyridinium- induced neuronal apoptosis in rat forebrain culture. Neuroscience. 2007;144:46-55.
43. Bodis-Wollner I, Chung E, Ghilardi MF, et al. Acetyl-levo-carnitine protects against MPTPinduced parkinsonism in primates. J Neural Transm Park Dis Dement Sect. 1991;3:63-72.
44. Zhang H, Jia H, Liu J, et al. Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson’s disease. J Cell Mol Med. 2008;14:215-25.
45. Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett. 1982;33:305-10.
46. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord. 1994;9:92-7.
47. Fitzmaurice PS, Ang L, Guttman M, et al. Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease. Mov Disord. 2003;18:969-76.
48. Hauser RA, Lyons KE, McClain T, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009;24:979-83.
49. Clark J, Clore EL, Zheng K, et al. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One. 2010;5:e12333.
50. Weisskopf MG, O’Reilly E, Chen H, et al. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007;166:561-7.
51. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66:1460-8.
52. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington’s disease progression. Mov Disord. 2010;25:224-8.
53. Bowman GL, Shannon J, Frei B, et al. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010; 19:1331-6.
54. Irizarry MC, Raman R, Schwarzschild MA, et al. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009;6:23-8.
55. Naoi M, Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in agedependent neurodegenerative disorders. Curr Pharm Des. 2010;16:2799-817.
56. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361:1268-78.
57. Naoi M, Maruyama W, Yi H, et al. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J Neural Transm Suppl. 2007; (72): 121-31.
58. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson’s disease with 18 F-fluorodeoxyglucose and positron emission tomography. Neurology. 1995;45: 1995-2004.
59. Klivenyi P, Siwek D, Gardian G, et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis. 2006;21:541-8.
60. Youdim MB, Bar Am O, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79:172-9.
61. Chau KY, Cooper JM, Schapira AH. Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int. 2010;57:525-9.
62. Ferrari-Toninelli G, Maccarinelli G, Uberti D, et al. Mitochondria-targeted antioxidant effects of S(−) and R(+) pramipexole. BMC Pharmacol. 2010;10:2.
63. Schapira A, Albercht S, Barone P, Comella C, Hsu H, Massey D, et al. Immediate vs. delayedstart pramipexole in early Parkinson’s disease: the PROUD study. Parkinsonism Relat Disord. 2009;15:S81.
64. Wang H, Larriviere KS, Keller KE, et al. R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS. Amyotroph Lateral Scler. 2008;9:50-8.
65. Parvez S, Winkler-Stuck K, Hertel S, et al. The dopamine-D2-receptor agonist ropinirole dose-dependently blocks the Ca2+-triggered permeability transition of mitochondria. Biochim Biophys Acta. 2010;1797:1245-50.
66. Tauskela JS. MitoQ - a mitochondria-targeted antioxidant. IDrugs. 2007;10:399-412.
67. Cassina P, Cassina A, Pehar M, et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci. 2008;28:4115-22.
68. Ghosh A, Chandran K, Kalivendi SV, et al. Neuroprotection by a mitochondria-targeted drug in a Parkinson’s disease model. Free Radic Biol Med. 2010;49:1674-84.
69. Petri S, Kiaei M, Damiano M, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2006;98:1141-8.
70. Manczak M, Mao P, Calkins MJ, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J Alzheimers Dis. 2010;20 Suppl 2: S609-31.
71. Arduino DM, Esteves AR, Oliveira CR, et al. Mitochondrial metabolism modulation: a new therapeutic approach for Parkinson’s disease. CNS Neurol Disord Drug Targets. 2010;9:105-19.
72. Hyson HC, Kieburtz K, Shoulson I, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington’s disease and healthy subjects. Mov Disord. 2010;25:1924-8.
73. Lee JM, Li J, Johnson DA, et al. Nrf2, a multi-organ protector? FASEB J. 2005;19:1061-6.
74. McGill JK, Beal MF. PGC-1alpha, a new therapeutic target in Huntington’s disease? Cell. 2006;127:465-8.
75. Chaturvedi RK, Calingasan NY, Yang L, et al. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington’s disease following chronic energy deprivation. Hum Mol Genet. 2010;19:3190-205.
76. St-Pierre J, Drori S, Uldry M, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127:397-408.
77. Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127:59-69.
78. Dali-Youcef N, Lagouge M, Froelich S, et al. Sirtuins: the ‘magnificent seven’, function, metabolism and longevity. Ann Med. 2007;39:335-45.
79. Kim D, Nguyen MD, Dobbin MM, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J. 2007;26: 3169-79.
80. Zheng B, Liao Z, Locascio JJ, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2011;2:52ra73.
81. Schintu N, Frau L, Ibba M, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur J Neurosci. 2009;29:954-63.
82. Jung TW, Lee JY, Shim WS, et al. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci. 2007;253:53-60.
83. Chan CS, Gertler TS, Surmeier DJ. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S63-70.
84. Surmeier DJ, Guzman JN, Sanchez-Padilla J, et al. What causes the death of dopaminergic neurons in Parkinson’s disease? Prog Brain Res. 2010;183:59-77.
85. Surmeier DJ, Guzman JN, Sanchez-Padilla J, et al. The origins of oxidant stress in Parkinson’s disease and therapeutic strategies. Antioxid Redox Signal. 2011;14:1289-301.
86. Ritz B, Rhodes SL, Qian L, et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67:600-6.
87. Guzman JN, Sanchez-Padilla J, Wokosin D, et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature. 2010;468:696-700.
88. Kyriakouli DS, Boesch P, Taylor RW, et al. Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Ther. 2008;15:1017-23.
89. Manfredi G, Fu J, Ojaimi J, et al. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet. 2002;30:394-9.
90. Mahata B, Mukherjee S, Mishra S, et al. Functional delivery of a cytosolic tRNA into mutant mitochondria of human cells. Science. 2006;314:471-4.
91. Minczuk M, Papworth MA, Miller JC, et al. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res. 2008;36:3926-38.
92. Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112:892-901.
93. Schulz JB, Henshaw DR, Matthews RT, et al. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995;132:279-83.
94. Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med. 2010;16:998-1000.
95. Su B, Wang X, Bonda D, et al. Abnormal mitochondrial dynamics - a novel therapeutic target for Alzheimer’s disease? Mol Neurobiol. 2010;41:87-96.
96. Shirendeb U, Reddy AP, Manczak M, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet. 2011;20:1438-55.
97. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12:9-14.
98. Narendra DP, Youle RJ. Targeting mitochondrial dysfunction: role for PINK1 and parkin in mitochondrial quality control. Antioxid Redox Signal. 2011;14:1929-38.
99. Haas RH, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/ III activity in early untreated Parkinson’s disease. Ann Neurol. 1995;37:714-22.
100. Henchcliffe C, Dikoma DC, Mao X, et al. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial function in Parknison’s disease. Ann N Y Acad Sci. 2008;1147:206-20.